Trial Profile
A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 15 Apr 2024
Price :
$35
*
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms O'HAND; ORATORIO-HAND
- Sponsors Roche
- 24 Aug 2023 Planned End Date changed from 4 Apr 2028 to 11 Nov 2030.
- 24 Aug 2023 Planned primary completion date changed from 20 Aug 2026 to 10 Dec 2027.
- 30 Mar 2023 The trial has been completed in Ireland, according to European Clinical Trials Database record.